Skip to main content
Premium Trial:

Request an Annual Quote

Cetek and Tularik Collaborate on Assays, Screening

NEW YORK, Feb. 6--Cetek Corporation will collaborate with Tularik in a project to develop assays and discover lead compounds, the company said today.

 

The partnership will apply Cetek's CE Assay, a capillary electrophoresis system to rank small molecule affinity for therapeutic target proteins, to develop lead compounds.

 

The companies did not reveal financial details nor discuss the therapeutic area for this collaboration.

 

Tularik is a publicly owned drug development company with research programs in cancer, viral disease, immune disorders, inflammation, obesity, diabetes and lipid disorders.

 

Cetek, based in Marlborough, Mass., is privately held. Its CE Assay system is the basis of a range collaborations with pharmaceutical and biotech firms.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.